Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Lessons on Who Benefit Most with Second Line and Later Therapies
Author
Howard (Jack) West, MD

One very important trial that has changed how we treat previously treated patients with advanced NSCLC has been a trial coded JMEI by Lilly, which sponsored this phase III randomized trial that directly compared second line treatment with alimta (pemetrexed) against the only FDA-approved second line treatment at that time, taxotere (docetaxel). Essentially identical in activity, this trial led to alimta's approval for lung cancer because it was associated with less frequent and severe drops in blood counts and fewer hospitalzations than with taxotere (abstract here). But from this trial we've also been able to glean additional information on who benefits more or less from second-line treatment.

Dr. Glen Weiss published a follow-up paper (available here) that analyzed several variables in the JMEI trial. Some findings were definitely anticipated: patients with the best performance status of 0 had a far better survival than patients with a modestly or more significantly compromised performance status of 1 or 2 (median survival 12.7 vs. 8.3 vs 2.6 months for 0/1/2, respectively) -- we knew that healthier patients do better and live longer.

Weiss Ann Oncol PS and survival

(Click on image to enlarge)

We also saw that patients who had previously had an objective response (complete or partial) did especially well, with a median survival of 15.8 months, compared to patients who achieved stable disease (median 10.5 months) or progressive disease (median 4.6 months) on first line chemo. So "responders respond", and the patients who did best early continue to do better, and those with aggressive disease initially tended to continue to do the least well.

Weiss Prior Response and OS

And you might expect that the patients who went the longest time between completing first line therapy and starting second line treatment did the best, since they'd have the slowest progressing disease. There was a modest difference there as well, with those who needed to move promptly to second line treatment (< 3 months) having a median survival of 6.9 months vs. a longer survival if you had a longer interval before needing second line treatment (9.2 and 9.3 months for 3-6 month and >6 month interval, respectively).

As has been seen in some other trials, such as the BR.21 trial of tarceva vs. placebo for 2nd or 3rd line therapy (abstract here), patients with adenocarcinomas had the longest median overall survival (9.1 months), followed by "other/mixed" (7.8 months), with squamous a little further behind (6.5 months). And women had a significantly better median survival compared with men, a full two month difference (9.4 vs 7.2 months). Age of younger than 70 vs. 70 or older didn't make a difference in overall survival.

There is significant attention in the paper on a trend toward better survival in the patients who received a combination of a platinum (cisplatin or carboplatin) and gemcitabine compared with a platinum and a taxane (such as taxol) or another platinum-based doublet:

Weiss JMEI survival and prior chemo

But this difference really didn't emerge as statistically significant.

One other issue came up in the further analysis of the trial, and that was the difference in outcomes with alimta vs. taxotere in patients 70 and over. I'll cover that next.

Next Previous link

Previous PostNext Post

Related Content

Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Imagine your body's defense system, the lymphatic system, suddenly turning against you. This is the reality for those facing lymphoma, a cancer of the immune system's crucial network. This article delves into the complexities of lymphoma, exploring its various forms, from the aggressive to the indolent, and examining the latest breakthroughs in treatment, including the groundbreaking POLARIX trial and cutting-edge therapies for relapsed cases. Whether you're a patient, a loved one, or simply curious about this complex disease, this comprehensive overview will provide valuable insights into the current state of lymphoma care and the promising future of research.
Image
Melanoma Video Library
Video
In these videos, Dr. Autumn Starnes gives an overview of melanoma's prevalence and risk factors. She also discusses the ABCDE method of self-screening for skin cancer, common misconceptions regarding people of color, and melanoma, and how a person can lower their risk of developing melanoma, among other relevant topics regarding melanoma.  To watch the complete playlist, click here. 

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Glad to help.  FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/

Hope to see...

Recent Comments

JOIN THE CONVERSATION
Glad to help.  FYI, I just…
By JanineT GRACE … on
I was searching for this,…
By LilahStapleton on
Hi and welcome.  I'm sorry…
By JanineT GRACE … on
Hi amitchouhan,

Welcome to…
By JanineT GRACE … on